Literature DB >> 6510415

Purification and structures of branched blood-group-B-active glycosphingolipids from human erythrocyte membranes.

P Hanfland, M Kordowicz, H Niermann, H Egge, U Dabrowski, J Peter-Katalinic, J Dabrowski.   

Abstract

Three different variants of complex, branched, highly blood-group-B-active glycosphingolipids (B-III, B-IV, and B-V) have been isolated from human erythrocytes by means of partition of their membranes in n-butanol/phosphate buffer, subsequent removal of nonpolar lipids and proteins by several steps of phase distribution, acetone or sodium acetate precipitation, peracetylation and repeated fractionation of all crude extracts by silicic acid and ion exchange column chromatography. Finally, peracetylated B-glycolipid fractions were purified to homogeneity by preparative silica gel high-performance thin-layer chromatography. Their structures were elucidated by gas chromatographical sugar analysis, by combined gas chromatography/mass spectrometry of partially methylated alditol acetates for the identification of glycosidic linkages, and by fast atom bombardment and electron impact mass spectrometry of the undegraded, permethylated substances in order to establish the molecular mass, sugar sequence, type of oligosaccharide chain, position of hexosyl branching points, number of N-acetyllatosamine units, as well as sphingosine and fatty acid patterns of the ceramide residues. 360-MHz 1H nuclear magnetic resonance spectroscopy in (2H)dimethylsulfoxide of deuterium-exchanged native B-III and B-IV identified all carbohydrate components, their sites of attachment, the anomeric nature of their glycosidic linkages and the sequential arrangement within the oligosaccharide chain. Furthermore, it established the nature of branching points within the carbohydrate sequence, and assigned the different typical saccharide branches to either the position 2 versus 3, or position 3 versus 6 of the 2,3-disubstituted or 3,6-disubstituted galactoses. The nature of the anomeric linkages and branching points of B-V was based upon the series of NMR data obtained from the B-I--B-IV analogues. All results thus establish the following structures: (formula; see text)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6510415     DOI: 10.1111/j.1432-1033.1984.tb08589.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  6 in total

1.  Detection of ABO blood group-active glycolipids extracted from red cell membrane and heat hematoma using TLC-immunostaining.

Authors:  M Ota; H Fukushima; I Yonemura; H Hasekura
Journal:  Z Rechtsmed       Date:  1988

2.  Helicobacter pylori and complex gangliosides.

Authors:  Niamh Roche; Jonas Angström; Marina Hurtig; Thomas Larsson; Thomas Borén; Susann Teneberg
Journal:  Infect Immun       Date:  2004-03       Impact factor: 3.441

3.  Norwalk virus-like particles bind specifically to A, H and difucosylated Lewis but not to B histo-blood group active glycosphingolipids.

Authors:  Jonas Nilsson; Gustaf E Rydell; Jacques Le Pendu; Göran Larson
Journal:  Glycoconj J       Date:  2009-12       Impact factor: 2.916

4.  Evolutionary relationship between the natural anti-Gal antibody and the Gal alpha 1----3Gal epitope in primates.

Authors:  U Galili; M R Clark; S B Shohet; J Buehler; B A Macher
Journal:  Proc Natl Acad Sci U S A       Date:  1987-03       Impact factor: 11.205

5.  Carbohydrate sequence of the prostate cancer-associated antigen F77 assigned by a mucin O-glycome designer array.

Authors:  Chao Gao; Yan Liu; Hongtao Zhang; Yibing Zhang; Michiko N Fukuda; Angelina S Palma; Radoslaw P Kozak; Robert A Childs; Motohiro Nonaka; Zhen Li; Don L Siegel; Peter Hanfland; Donna M Peehl; Wengang Chai; Mark I Greene; Ten Feizi
Journal:  J Biol Chem       Date:  2014-04-21       Impact factor: 5.157

6.  The repertoire of glycosphingolipids recognized by Vibrio cholerae.

Authors:  John Benktander; Jonas Ångström; Hasse Karlsson; Omid Teymournejad; Sara Lindén; Michael Lebens; Susann Teneberg
Journal:  PLoS One       Date:  2013-01-21       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.